Wounds - Pipeline Review, H2 2019

December 2019 | 224 pages | ID: W00F0C8433BEN
Global Markets Direct

Abstracts

Wounds - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wounds - Pipeline Review, H2 2019, provides an overview of the Wounds (Dermatology) pipeline landscape.

Wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/organs caused by surgery, a blow, a cut, chemicals, heat/cold, friction/shear force, pressure or as a result of disease, such as leg ulcers or carcinomas. Signs and symptoms include redness or red streaks on the skin surrounding the wound, increased swelling to tenderness at the wound site, pus-like drainage or a foul smell from the wound and body chills or fever.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wounds - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Wounds (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wounds (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Wounds and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 7, 1, 52, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 4 molecules, respectively.

Wounds (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Wounds (Dermatology).
• The pipeline guide reviews pipeline therapeutics for Wounds (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Wounds (Dermatology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Wounds (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Wounds (Dermatology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Wounds (Dermatology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Wounds (Dermatology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Wounds - Overview
Wounds - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Wounds - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Wounds - Companies Involved in Therapeutics Development
Agile Sciences Inc
Aiviva BioPharma Inc
AlgiPharma AS
Allander Biotechnologies LLC
Alliance Pharma Plc
Ankasa Regenerative Therapeutics Inc
Apidel SA
Aposcience AG
Araim Pharmaceuticals Inc
Arava Bio-Tech Ltd
Armata Pharmaceuticals Inc
Arrevus Inc
Avalon GloboCare Corp
Axolo Pharma Inc
Biomendics LLC
Biotec Pharmacon ASA
Canton Biotechnologies Inc
Cellphire Inc
Clene Nanomedicine Inc
Crioestaminal Saude e Tecnologia SA
Daewoong Pharmaceutical Co Ltd
Destiny Pharma Plc
Exicure Inc
Exopharm Ltd
Factor Therapeutics Ltd
FortuneRock (China) Ltd
Gene Signal International SA
Hana Pharm Co Ltd
Helixmith Co Ltd
Huons Global Co Ltd
Ilya Pharma AB
Intralytix Inc
Kine Sciences
LayerBio Inc
Lipid Biologics LLC
Living Cell Technologies Ltd
Madam Therapeutics BV
MangoGen Pharma Inc
Marizyme Inc
MediaPharma SRL
MediWound Ltd
MicroCures Inc
Miragen Therapeutics Inc
Novion Technologies Inc
Novopyxis Inc
Omeros Corp
Opal Biosciences Ltd
Pacific Northwest Biotechnology LLC
PhagoMed Biopharma GmbH
Phoenicia Biosciences Inc
QBiotics Ltd
Remedor Biomed Ltd
Reponex Pharmaceuticals Aps
Resolys Bio Inc
Riptide Bioscience Inc
Roji Ltd
Scarless Laboratories Inc
SomaGenics Inc
Synedgen Inc
TGV-Inhalonix Inc
Thesan Pharmaceuticals Inc
Topadur Pharma AG
Transwell Biotech Co Ltd
Traverse Biosciences Inc
Tumorend LLC
Valitor Inc
Vascular BioSciences
Vasomune Inc
viDA Therapeutics Inc
Yabao Pharmaceutical Group Co Ltd
Zih Yuan Tang Biotechnology Co Ltd
ZZ Biotech LLC
Wounds - Drug Profiles
Wounds - Dormant Projects
Wounds - Discontinued Products
Wounds - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Wounds, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Wounds - Pipeline by Agile Sciences Inc, H2 2019
Wounds - Pipeline by Aiviva BioPharma Inc, H2 2019
Wounds - Dormant Projects, H2 2019
Wounds - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Wounds, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019